🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ran into ⁦⁦Sumanta K. Pal, MD, FASCO⁩ for a larger reunion! ⁦ASCO⁩ LDP was a great experience and great to catch up! ⁦Neelima Denduluri⁩ ⁦Suzanne Cole, MD, FACP, FASCO⁩

I signed ASCO’s letter from America’s cancer doctors & providers urging policymakers to end the drug shortage crisis. Patients are still struggling to get the treatments they need. Add your voice to the push for solutions & sign the letter! #ASCOAdvocacy asco.quorum.us/campaign/56411…

DADIO is happening! Building upon success of EV and SG adding pembro - learn more at poster board 307A - TPS4618 ASCO Toni Choueiri, MD joaquim bellmunt Dana-Farber Lank Center for Genitourinary Oncology Guru P. Sonpavde, MD

A great way to start day 3 at #ASCO24 - beautiful 6+ mile run with Benjamin L Maughan Missing Sumanta K. Pal, MD, FASCO

Anyone up for a run at #WorldGU24? Too hard to pass up a run around Central Park as a warmup for Pan-Mass Challenge this weekend! Anyone interested let’s meet in JW lobby at 515

930 am and already over 40 miles in to Pan-Mass Challenge with Toni Choueiri, MD Michael Serzan, MD profile.pmc.org/BM0366

87 miles down all before 1 pm for Pan-Mass Challenge Looking forward to day 2 tomorrow with Michael Serzan, MD and Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology profile.pmc.org/BM0366

60 miles before 9 am l Pan-Mass Challenge with Michael Serzan, MD Toni Choueiri, MD 20 to go!

Getting ready for the WEEI Dana-Farber telethon to raise money for cancer research! #KCANCER

First presentation of ESMO - Eur. Oncology - addition of nivoluamb to tiovzanib does not improve outcomes following progression on immunotherapy; tivozanib with encouraging PFS of over 9 months when used second line - full data in The Lancet Toni Choueiri, MD Aly-Khan Lalani Dana-Farber Lank Center for Genitourinary Oncology

Nivo/ipi improves 12 month overall survival rate vs SOC with ORR 33%; responses seen in 7 patients (25% ORR) with chromophobe RCC. PDL1 may be a predictive biomarker #ESMO2024 Toni Choueiri, MD Aly-Khan Lalani

NKT2152 an oral hf2 inhibitor with half life of 38 days has activity in heavily treated ccRCC with ORR 20% (26% with longer followup) with no unexpected toxicity. Trials ongoing exploring dose and activity following belzutifan - open Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD

Beautiful AM for a 5k to start the day at #ESMO2024 OncoAlert Michael Palliola

Up now - DAD update for #ESMO24! With 22 month followup SG+EV for 2L+ active with no new toxicity signals. ORR 70% with 4 CR; 6 patients with ongoing response - median DOR 10 months (range 3-33+). DADIO coming soon! joaquim bellmunt Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology

Thanks Pedro C Barata, MD MSc FACP for highlighting CAN-I! Poster up at #ESMO24; with extended followup Cabo/nivo/ipi with ORR 21% in RCC with divergent histologies though significant toxicity. Work ongoing correlating pdl1 and genomics with response Toni Choueiri, MD Wenxin (Vincent) Xu Dana-Farber Lank Center for Genitourinary Oncology

Great way to end #ESMO2024 with sunrise run along the beach Benjamin L Maughan

Great way to start final day of #IKCSNA24 with 5 mile run in Louisville with Benjamin L Maughan Michael Palliola

STRIKE activated; download docs today! Alliance for Clinical Trials in Oncology National Cancer Institute Can we prevent more recurrences with addition of 6 months of Tivozanib to 1 year of pembrolizumab in patients with resected high risk ccRCC? Dan George Jonathan Rosenberg MD Matt Galsky Toni Choueiri, MD

Weather looks to be ok! Let’s start day 2 of #GU25 with a run along the Embarcadero - meet in Marriott lobby at 545! ASCO Benjamin L Maughan Sumanta K. Pal, MD, FASCO Toni Choueiri, MD

It was a great run - join us tomorrow am at 545 in Marriott Marquis lobby for all run along the Embarcadero to finish off #GU25 ASCO Benjamin L Maughan Sumanta K. Pal, MD, FASCO